Centogene 過去の業績

過去基準チェック /06

Centogeneの収益は年間平均-18%の割合で減少していますが、 Healthcare業界の収益は年間増加しています。収益は年間5.4% 0.8%割合で増加しています。

主要情報

-18.0%

収益成長率

-9.8%

EPS成長率

Healthcare 業界の成長	8.5%
収益成長率	0.8%
株主資本利益率	n/a
ネット・マージン	-73.2%
前回の決算情報	31 Dec 2023

Recent updates

Take Care Before Jumping Onto Centogene N.V. (NASDAQ:CNTG) Even Though It's 36% Cheaper

Aug 06

Centogene N.V.'s (NASDAQ:CNTG) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Feb 16

収支内訳

Centogene の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

OTCPK:CNTG.F 収益、費用、利益 ( )EUR Millions
日付	収益	収益	G+A経費	研究開発費
31 Dec 23	49	-36	46	12
30 Sep 23	50	-38	45	14
30 Jun 23	51	-40	45	15
31 Mar 23	49	-40	44	16
31 Dec 22	47	-39	42	17
30 Sep 22	-15	-44	46	20
30 Jun 22	2	-58	49	20
31 Mar 22	190	-44	55	20
31 Dec 21	42	-57	54	19
30 Sep 21	162	-40	59	17
30 Jun 21	168	-24	57	18
31 Mar 21	126	-27	55	17
01 Jan 21	38	-60	49	15
30 Sep 20	73	-30	43	14
30 Jun 20	49	-28	39	11
31 Mar 20	50	-24	35	11
31 Dec 19	49	-21	33	10
30 Sep 19	44	-19	30	9
30 Jun 19	45	-16	30	8
31 Mar 19	43	-13	28	7
31 Dec 18	40	-11	26	6
30 Sep 18	39	-9	23	7
31 Dec 17	32	-5	15	6
31 Dec 16	28	-5	14	6

質の高い収益: CNTG.Fは現在利益が出ていません。

利益率の向上: CNTG.Fは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: CNTG.Fは利益が出ておらず、過去 5 年間で損失は年間18%の割合で増加しています。

成長の加速: CNTG.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: CNTG.Fは利益が出ていないため、過去 1 年間の収益成長をHealthcare業界 ( 10.3% ) と比較することは困難です。

株主資本利益率

高いROE: CNTG.Fの負債は資産を上回っているため、自己資本利益率を計算することは困難です。

Centogene 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Full year 2022 earnings: EPS exceeds analyst expectations

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings: EPS and revenues exceed analyst expectations

Second quarter 2021 earnings released: €0.37 loss per share (vs €0.52 loss in 2Q 2020)

Recent updates

Charme IV Fund, a fund managed by Charme Capital Partners SGR S.p.A. agreed to acquire Centogene GmbH from Centogene N.V. (OTCPK:CNTG.F).

Charme IV Fund, a fund managed by Charme Capital Partners SGR S.p.A. agreed to acquire Centogene GmbH from Centogene N.V. (OTCPK:CNTG.F).

Centogene N.V. Announces Term Expires of Jose Miguel Coego Rios as Chief Financial Officer

Centogene N.V Announces Data from the Rostock International Parkinson's Disease (ROPAD)

Centogene Receives Delisting Notice from Nasdaq, Effective at the Open of Trading on August 8, 2024

Take Care Before Jumping Onto Centogene N.V. (NASDAQ:CNTG) Even Though It's 36% Cheaper

Centogene Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors

Centogene N.V. Provides Earnings Guidance for the Year 2024

Centogene Biodatabank Grows to Incorporate Disease Insights from over 850,000 Diverse Patients

Centogene N.V. announced delayed 20-F filing

New minor risk - Financial data availability

Centogene N.V.'s (NASDAQ:CNTG) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Centogene N.V. Provides Earnings Guidance for the Full Year 2023

Centogene N.V. (NASDAQ:CNTG) Might Not Be As Mispriced As It Looks

Centogene N.V. Announces Changes to Supervisory Board

Centogene N.V.'s Frontotemporal Dementia Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

Centogene N.V. Announces the Discovery of A New Form of Early-Onset Dystonia and Parkinsonism

Centogene N.V. Expands Multiomic Diagnostic Portfolio with Newly-Launched Transcriptomic Offering

New major risk - Revenue and earnings growth

Centogene N.V. Reaffirms Revenue Guidance for the Year 2023

Centogene N.V. Announces Publication Establishing Lyso-Gb1 as A Predictive Biomarker for Gaucher Disease Patients

Centogene N.V. Announces Resignation of Berndt Modig from Supervisory Board

Centogene Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort

Centogene N.V. announced that it expects to receive $30 million in funding from Lifera

New minor risk - Shareholder dilution

Centogene Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

Centogene N.V., Annual General Meeting, Jun 30, 2023

Centogene N.V., Annual General Meeting, Jun 30, 2023

Bettina Goerner Decides to Step Down as Chief Data Officer of Centogene N.V., Effective May 26, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Centogene N.V. Provides Revenue Guidance for Fiscal Year 2023

Centogene Regains Compliance with Nasdaq Listing Requirements

Centogene N.V. Appoints Prof. Peter Bauer, Chief Medical and Genomic Officer to its Management Board and as Managing Director of the subsidiary Centogene GmbH

Centogene N.V. Announces Resignation of Florian Vogel as Chief Process Officer, Effective February 28, 2023

Twist Bioscience and Centogene Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Centogene N.V. Provides Revenue Guidance for the Fiscal Year 2022

Centogene Receives Nasdaq Non-Compliance Notice

Centogene N.V. Announces Changes to Supervisory Board

Centogene Launches Rare and Neurodegenerative Disease Biodata Network

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Centogene N.V. Reaffirms Earnings Guidance for the Year 2022

Centogene GAAP EPS of -€0.28, revenue of €10.32M

Centogene N.V. Announces Appointment of Miguel Coego Rios as Managing Director

Centogene N.V., Annual General Meeting, Jun 22, 2022

Centogene N.V., Annual General Meeting, Jun 22, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Centogene N.V. Provides Earnings Guidance for the Year 2022

Centogene N.V. Appoints Miguel Coego Rios as Executive Vice President of Finance & Legal

Centogene N.V. announced that it has received €14.915363 million in funding from DPE Deutsche Private Equity GmbH, TVM Life Science Management Inc, Careventures S.A.

Centogene N.V. Announces the Global Release of CentoCloud, A SaaS Platform Enabling Decentralized Analysis, Interpretation, and Reporting of Genomic Variants Linked to Rare Diseases

Third quarter 2021 earnings: EPS and revenues exceed analyst expectations

Centogene N.V. Provides Earnings Guidance for the Full Year 2021

Consensus forecasts updated

Is Centogene (NASDAQ:CNTG) Using Debt In A Risky Way?

Second quarter 2021 earnings released: €0.37 loss per share (vs €0.52 loss in 2Q 2020)

Centogene N.V. Provides Revenue Guidance for the Second Half and Full Year of 2021

Chief Scientific Officer Philip Lambert has left the company

Executive Officer Richard Stoffelen has left the company

Is Centogene (NASDAQ:CNTG) Using Debt Sensibly?

Consensus forecasts updated

First quarter 2021 earnings released: €0.22 loss per share (vs €0.43 loss in 1Q 2020)

Centogene N.V. Announces Unaudited Consolidated Impairment Charges for the First Quarter Ended March 31, 2021

Centogene reports Q1 results

Centogene N.V. Initiates EFRONT Study to Identify Patients with Genetic Forms of Frontotemporal Dementia

Centogene N.V. Launches New CentoXome

Centogene, Alector initiate EFRONT study in frontotemporal dementia

Centogene to nominate Rene Just as CFO at the upcoming Annual General Meeting

過去基準チェック /06